Avita Medical Ltd (DE:51KA)
NASDAQ:51KA
51KA Stock Chart & Stats
€4.00
-€4.00(-31.25%)
At close: 4:00 PM EST
€4.00
-€4.00(-31.25%)
Day’s Range― - ―
52-Week Range€2.68 - €5.50
Previous CloseN/A
Volume550.00
Average Volume (3M)0.00
Market Cap
€111.08M
Enterprise Value€101.24M
Total Cash (Recent Filing)€14.26M
Total Debt (Recent Filing)€1.98M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 06, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding30,776,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-5.77
Price to Sales (P/S)1.34
P/FCF Ratio-2.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.15Price Target Upside53.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.91
Revenue Forecast (FY)€71.09M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsVery high gross margins (low-80% overall; RECELL ~85%) reflect attractive unit economics for each procedure. This durable margin profile provides room to fund commercialization and absorb fixed costs, meaning higher utilization can translate into sustained operating leverage over time.
Recurring Consumables ModelThe device-plus-single-use consumables model creates recurring, procedure-tied revenue and higher lifetime value per account. As hospitals and burn centers increase utilization, the repeatable consumables stream supports predictable revenue growth and scalable gross dollars over the medium term.
Improving Operating DisciplineManagement has reduced operating expenses (~11% YoY) while delivering sequential revenue growth and a smaller net loss, and has reaffirmed FY26 guidance. Sustained cost control combined with revenue momentum improves runway and increases the probability of reaching breakeven as scale benefits accrue.
Bears Say
Negative Shareholders' EquityShareholders' equity has turned negative, reflecting accumulated losses that have materially eroded the capital base. Negative equity reduces financial flexibility, raises the risk of covenant or refinancing stress, and increases the likelihood management must pursue dilutive financing to fund growth.
Persistent Cash BurnThe company is a persistent cash burner (TTM FCF ≈ -$31M) with Q1 cash use near $9.9M and limited cash (~$14.3M). This dynamic necessitates external funding or reliance on credit facilities, constraining strategic options and elevating execution and refinancing risk during scaling.
Early-stage Product Risk & Mix PressureNew products (Cohealyx, PermeaDerm) are in early commercialization and currently lower reported margins via mix and reserves. Adoption is account-by-account and requires education; this mix pressure can delay margin expansion and postpone sustainable profitability until scale and payor/provider uptake improve.
Avita Medical News
51KA FAQ
What was Avita Medical Ltd’s price range in the past 12 months?
Avita Medical Ltd lowest stock price was €2.68 and its highest was €5.50 in the past 12 months.
What is Avita Medical Ltd’s market cap?
Avita Medical Ltd’s market cap is €111.08M.
When is Avita Medical Ltd’s upcoming earnings report date?
Avita Medical Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Avita Medical Ltd’s earnings last quarter?
Avita Medical Ltd released its earnings results on May 14, 2026. The company reported -€0.301 earnings per share for the quarter, missing the consensus estimate of -€0.251 by -€0.05.
Is Avita Medical Ltd overvalued?
According to Wall Street analysts Avita Medical Ltd’s price is currently Undervalued.
Does Avita Medical Ltd pay dividends?
Avita Medical Ltd does not currently pay dividends.
What is Avita Medical Ltd’s EPS estimate?
Avita Medical Ltd’s EPS estimate is -0.26.
How many shares outstanding does Avita Medical Ltd have?
Avita Medical Ltd has 30,776,690 shares outstanding.
What happened to Avita Medical Ltd’s price movement after its last earnings report?
Avita Medical Ltd reported an EPS of -€0.301 in its last earnings report, missing expectations of -€0.251. Following the earnings report the stock price went up 2.797%.
Which hedge fund is a major shareholder of Avita Medical Ltd?
Currently, no hedge funds are holding shares in DE:51KA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avita Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.15 (53.67% Upside)
€6.15 (53.67% Upside)
Blogger Sentiment
Bullish
DE:51KA Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €95.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.62%
12-Months-Change
Fundamentals
Return on Equity
305.45%
Trailing 12-Months
Asset Growth
-25.90%
Trailing 12-Months
Company Description
Avita Medical Ltd
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
51KA Company Deck
51KA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and commercial developments: sequential and year-over-year revenue growth, reduced operating expenses, improving net loss, RECELL reimbursement normalization, encouraging Cohealyx clinical data, BARDA partnership, and a credit facility structured with meaningful covenant headroom. Offsetting these positives are margin pressure from product mix and inventory reserves, a seasonal cash burn with a modest cash balance, and the early-stage commercialization risk of Cohealyx and PermeaDerm requiring further adoption and data to realize scale. Overall, the company appears to be transitioning from stabilization to execution with tangible early momentum but still faces near-term cash and margin headwinds as new products scale.View all DE:51KA earnings summaries51KA Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
51KA Stock 12 Month Forecast
Average Price Target
€6.15
▲(53.67% Upside)
Technical Analysis
Options Prices
Currently, No data available
---